Can gut markers show early if a UC treatment works?
Part of Digestive system clinical trials.
This study looks at stool samples to see if certain markers can quickly tell whether a biologic medicine is starting to work for moderate-to-severe ulcerative colitis. If successful, this could help doctors make faster, smarter treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with ulcerative colitis and currently have moderate-to-severe symptoms.
- You are about to start treatment with either vedolizumab or infliximab within 7 days.
- You have not used a biologic before, or you have only tried one type called a TNF-alpha inhibitor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether early stool tests (fecal immunochemical test and calprotectin) can predict when ulcerative colitis symptoms might return. It is for people who have never taken biologic medications.
This study looks at whether a simple stool test can tell if treatment is healing the gut lining in people with moderate to severe ulcerative colitis who are starting their first biologic medicine. If it works, this test might help doctors adjust treatment earlier.
This study tests whether using a simple stool test to guide treatment is better than usual care for people with ulcerative colitis in remission. It aims to keep you in remission longer and prevent flare-ups.
This study tests whether a substance in your urine can help measure how active your ulcerative colitis is. Researchers hope this simple urine test might become a useful tool to track your disease without more invasive procedures.
This study compares four newer biologic medications (infliximab, filgotinib, vedolizumab, and ustekinumab) to find which works best as a first biologic treatment for ulcerative colitis that hasn't responded well to standard drugs. It aims to help doctors choose the right biologic for each patient.
This study tests non-invasive tools to find active inflammation in people with Crohn's disease or ulcerative colitis. You may need to give extra stool samples before your colonoscopy and calprotectin test.
Hear when a new FIT trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.